Polyrizon Ltd. PLRZ 深 滬
已收盤 04-02 16:00:00 美东时间
12.08
-0.530
-4.20%
華盛通- 最 高12.88
- 今 開12.02
- 成交量 3.80万股
- 最 低 11.635
- 昨 收 12.61
- 總市值 1959.62万
- 52周最高 2235.00
- 市盈率 靜 --
- 換手率 2.34%
- 52周最低 2.88
- 委 比 -95.12%
- 總股本 162.22万
- 歷史最高 7200.00
- 量 比 1.25
- 振 幅 9.87%
- 歷史最低 4.80
- 每 手 1
- 風險率 229.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Polyrizon Provides 2025 and Recent Highlights
Polyrizon Ltd. reported a strong end to 2025 with $17.5 million in cash, a debt-free balance sheet, and significant progress in its nasal spray programs. Key achievements include successful FDA meetings for its allergy and viral blockers, GMP manufacturing for clinical trials, and positive preclinical results for its hydrogel technology. The company also announced branding for its allergy blocker (NASARIX™) and strategic investments in high-growt...
03-26 13:23
Polyrizon Signs Memorandum Of Understanding To Acquire Up To 20% Of Colugo Systems For $6M In Potential Cash/Share Issuance Combination
Under the terms of the MOU, two shareholders will sell to Polyrizon approximately 20% of the outstanding share capital of Colugo on a fully-diluted basis. The aggregate purchase price for the Colugo shares is up to US
03-24 20:53
Polyrizon Signs Deal With Contract Research Organization To Carry Out Package Of Preclinical Biocompatibility Studies In Accordance With ISO 10993 Standards, GLP Requirements
Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global
03-17 20:27
Polyrizon Completes GMP Clinical Material for Planned U.S. Intranasal Study
Polyrizon Ltd. ( ($PLRZ) ) just unveiled an announcement. Polyrizon Ltd., a pre...
03-10 20:44
Polyrizon Announces Production Of Good Manufacturing Practice Batch Of Clinical Trial Material For Its Lead Product Candidate
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing
03-10 19:57
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Polyrizon Ltd., a pre-clinical-stage biotech company developing intranasal solutions, announced the successful production of a GMP batch of clinical trial material for its lead product candidate. This milestone follows a manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S and supports the company's planned U.S. clinical study later this year. The GMP batch demonstrates batch-to-batch consistency and product stability, aligning with t...
03-10 11:55
Polyrizon Announces Results From Comparative Study Evaluating Regional Nasal Deposition Profile Of Naloxone Formulation Versus Commercial Reference Product
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the
02-26 21:15
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the br...
02-18 00:32
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 6.9% to $1....
02-14 05:06
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI
Polyrizon Ltd. ( ($PLRZ) ) has shared an update. On February 6, 2026, Polyrizon...
02-06 21:23
